ChiCTR2500104208 版本V1.0 版本创建时间2025/06/12 15:05:54 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500104208 

最近更新日期:

Date of Last Refreshed on:

2025-06-12 15:05:27 

注册时间:

Date of Registration:

2025-06-12 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

丙泊酚联合阿芬太尼靶控输注对比间断推注在胃肠镜检查中的应用效果

Public title:

The effect of propofol combined with alfentanil target-controlled infusion compared with intermittent bolus injection in gastroenteroscopy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

丙泊酚联合阿芬太尼靶控输注对比间断推注在胃肠镜检查中的应用效果

Scientific title:

The effect of propofol combined with alfentanil target-controlled infusion compared with intermittent bolus injection in gastroenteroscopy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

申祥花 

研究负责人:

张二飞 

Applicant:

Shen Xianghua 

Study leader:

Zhang Erfei 

申请注册联系人电话:

Applicant telephone:

+86 150 2911 4959

研究负责人电话:

Study leader's telephone:

+86 138 9117 0975

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

294863670@qq.com

研究负责人电子邮件:

Study leader's E-mail:

zhangerfei09@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

陕西省延安市宝塔区北大街43号

研究负责人通讯地址:

陕西省延安市宝塔区北关街43号

Applicant address:

43 Peking University Street, Baota District, Yan'an City, Shaanxi Province

Study leader's address:

43 Beiguan Street, Baota District, Yan'an City, Shaanxi Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

延安大学附属医院

Applicant's institution:

Affiliated Hospital of Yan'an University

研究负责人所在单位:

延安大学附属医院

Affiliation of the Leader:

Affiliated Hospital of Yan'an University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

IIT—202503012

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

延安大学附属医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Affiliated Hospital of Yan'an University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-03-28 00:00:00

伦理委员会联系人:

王莉

Contact Name of the ethic committee:

Wang Li

伦理委员会联系地址:

陕西省延安市北关街43号

Contact Address of the ethic committee:

No. 43, Beiguan Street, Yan'an City, Shaanxi Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 911 288 1106

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

延安大学附属医院

Primary sponsor:

Affiliated Hospital of Yan'an University

研究实施负责(组长)单位地址:

陕西省延安市宝塔区北关街43号

Primary sponsor's address:

43 Beiguan Street, Baota District, Yan'an City, Shaanxi Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

陕西

市(区县):

延安市

Country:

China

Province:

Shaanxi

City:

Yan'an

单位(医院):

延安大学附属医院

具体地址:

陕西省延安市宝塔区北关街43号

Institution
hospital:

Affiliated Hospital of Yan'an University

Address:

43 Beiguan Street, Baota District, Yan'an City, Shaanxi Province

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-selected topics (self-funded)

Target disease:

hypoxemia

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

本研究通过观察丙泊酚联合阿芬太尼靶控输注在胃肠镜检查中的临床效果,为无痛胃肠镜麻醉提供更佳的给药方式。  

Objectives of Study:

This study observed the clinical effect of propofol combined with alfentanil target-controlled infusion in gastroenteroscopy, providing a better way of administration for painless gastroenteroscopic anesthesia.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

① 患者要求做无痛胃肠镜检; ② 年龄20-70岁; ③ BMI:18-28kg/m2; ④ 美国麻醉医师协会(American Society of Anesthesiologists,ASA)分级Ⅰ~Ⅲ级; ⑤ 签署麻醉知情同意书;

Inclusion criteria

1.The patient requested a painless gastroenteroscopy; 2. Age 20-70 years old; 3. BMI: 18-28kg/m2; 4. The American Society of Anesthesiologists (ASA) grades I to III; 5. Sign the informed consent form for anesthesia;

排除标准:

① 严重心血管疾病; ② 预计困难气道; ③ 长期服用阿片类药物过敏体质的患者; ④ 酗酒史; ⑤ 哮喘史; ⑥ 近期上呼吸道感染; ⑦ 糖尿病病史或筛选期空腹血糖≥11.1mmol/L; ⑧ 高血压病史或筛选期SBP≥140mmHg和/或DBP≥90mmHg; ⑨ 服用利血平的高血患者; ⑩ 筛选期开始前2年内有吸毒史和酗酒; ? 史妊娠期或哺乳期; ? 甲状腺功能亢进病史; ? 精神系统疾病及长期服用精神类药物史及认知功能障碍; ? 睡眠呼吸暂停; ? 慢性肺部疾病; ? 癫痫病史; ? 有严重肝肾功能不全; ? 6个月内发生过脑梗或心梗的患者;

Exclusion criteria:

1. severe cardiovascular disease; 2. Expected difficult airway; 3. Patients with long-term opioid allergy; 4. History of alcoholism; 5. History of asthma; 6.Recent upper respiratory tract infections; 7.Fasting blood glucose ≥ 11.1mmol/L during diabetes history or screening period; 8.Hypertensive history or screening period SBP >= 140mmHg and/or DBP >= 90mmHg; 9.Patients with high blood pressure who take reserpine; 10.A history of drug and alcohol abuse within two years before the start of the screening period; 11.History of pregnancy or breastfeeding; 12.History of hyperthyroidism; 13.Mental illness, long-term use of psychotropic drugs, and cognitive impairment; 14.Sleep apnea; 15.Chronic lung diseases; 16.History of epilepsy; 17.Have severe hepatorenal insufficiency; 18.Patients who have had a cerebral or myocardial infarction within 6 months.

研究实施时间:

Study execute time:

From 2025-03-29 00:00:00 To 2026-02-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-04-02 00:00:00 To 2026-02-01 00:00:00  

干预措施:

Interventions:

组别:

靶控输注组

样本量:

94

Group:

Target-controlled infusion group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

间断推注组

样本量:

94

Group:

Intermittent bolus group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

陕西 

市(区县):

延安市 

Country:

China 

Province:

Shaanxi  

City:

Yan'an 

单位(医院):

延安大学附属医院 

单位级别:

三甲 

Institution
hospital:

Affiliated Hospital of Yan'an University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术中低氧血症发生率(定义为术中SpO2<90%大于30s)

指标类型:

主要指标

Outcome:

Intraoperative incidence of hypoxemia (defined as intraoperative SpO2 < 90% greater than 30s)

Type:

Primary indicator

测量时间点:

手术期间

测量方法:

脉搏血氧饱和度仪的探头夹在患者的手指监测

Measure time point of outcome:

During surgery

Measure method:

The pulse oximeter probe is clipped to the patient's finger for monitoring

指标中文名:

术中低血压发生率(定义为MAP<65m,持续时间大于1min)

指标类型:

主要指标

Outcome:

Intraoperative hypotension (defined as MAP < 65m, duration greater than 1 min)

Type:

Primary indicator

测量时间点:

手术期间

测量方法:

监护仪袖带测量血压

Measure time point of outcome:

During surgery

Measure method:

Monitor cuff measures blood pressure

指标中文名:

麻醉期间不同时刻MAP,HR,SpO2

指标类型:

次要指标

Outcome:

MAP, HR, SpO2 at different times during anesthesia

Type:

Secondary indicator

测量时间点:

手术期间

测量方法:

监护仪脉搏血氧饱和度仪和袖带测量

Measure time point of outcome:

During surgery

Measure method:

Monitor pulse oximeter and cuff measurement

指标中文名:

麻醉期间标记事件(睫毛反射消失时间、胃肠镜总检查时间、患者苏醒时间、离室时间、丙泊酚总用量,阿芬太尼总用量)

指标类型:

次要指标

Outcome:

Marker events during anesthesia (eyelash reflex disappearance time, total gastroenteroscopy time, patient recovery time, time away from the room, total propofol dosage, total alfentanil dosage)

Type:

Secondary indicator

测量时间点:

手术期间

测量方法:

次要研究者记录

Measure time point of outcome:

During surgery

Measure method:

Secondary Investigator Record

指标中文名:

术中不良反应(心动过缓,呼吸暂停,注射痛,体动反应,呛咳反应))

指标类型:

次要指标

Outcome:

Intraoperative adverse reactions (bradycardia, apnea, injection pain, motor response, cough response)

Type:

Secondary indicator

测量时间点:

手术期间

测量方法:

次要研究者观察记录

Measure time point of outcome:

During surgery

Measure method:

Secondary investigator observation record

指标中文名:

术后不良反应(恶心呕吐,头痛头晕,腹胀腹痛,咽喉痛)

指标类型:

次要指标

Outcome:

Postoperative adverse reactions (nausea, vomiting, headache, dizziness, bloating, abdominal pain, sore throat)

Type:

Secondary indicator

测量时间点:

术后24小时内

测量方法:

次要研究者电话随访

Measure time point of outcome:

Within 24 hours after surgery

Measure method:

Secondary Investigator Telephone Follow-up

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

None

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

without

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究结束后6个月,经研究者同意后可邮箱获取

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

6 months after the end of the study, it can be obtained by email with the consent of the investigator

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集后保存在病例记录表以及电子采集和管理系统中

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

After data collection, it is stored in case records and electronic collection and management systems

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-06-12 15:05:27